Pharmaceutical giant AstraZeneca has announced its plan to build a $1.5 billion (SGD 2 billion) end-to-end manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-gen treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody. Construction is to start by end-2024.